No black box warning on record for Norelgestromin And Ethinly Estradiol

As of the latest FDA labeling reviewed, Norelgestromin And Ethinly Estradiol (NORELGESTROMIN AND ETHINLY ESTRADIOL) does not carry a black box warning. Standard warnings and precautions still apply — see the full Norelgestromin And Ethinly Estradiol medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Vascular risks: Stop norelgestromin and ethinyl estradiol if a thrombotic event occurs. Stop at least 4 weeks before and through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding. Consider cardiovascular risk factors before initiating in all women, particularly those over 35 years. (5.1) Liver disease: Discontin

No black box warning on record for Norelgestromin And Ethinly Estradiol

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Vascular risks: Stop norelgestromin and ethinyl estradiol if a thrombotic event occurs. Stop at least 4 weeks before and through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding. Consider cardiovascular risk factors before initiating in all women, particularly those over 35 years. (5.1) Liver disease: Discontin

Norelgestromin And Ethinly Estradiol Black Box Warning

No black box warning on record for Norelgestromin And Ethinly Estradiol

Other warnings & precautions

Norelgestromin And Ethinly Estradiol Black Box Warning

No black box warning on record for Norelgestromin And Ethinly Estradiol

Other warnings & precautions